Avian Stem Cell Microtissues for Scalable Cultured Meat
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The cultured meat industry faces challenges in producing scalable, cost-effective, and consumer-acceptable cell cultures due to limitations in cell origin, culture conditions, and scalability, particularly with avian embryonic stem cells, which are underutilized and require improved methods for large-scale production and differentiation.
Innovation Solution
A method is developed to produce pluripotent stem cell aggregates and microtissues using non-human stem cells, specifically avian embryonic stem cells, by growing them in suspension without matrix adherence, reducing adhesion molecule expression, and using growth factors to achieve rapid doubling times and differentiation into muscle, fat, and connective tissue, while eliminating animal-derived components from the culture medium.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If avian embryonic stem cells are used for cultured meat production, then self-renewal capacity and differentiation potential are improved, but scalability and large-volume culture capability are insufficient
Solution Approach 1:
The patent applies parameter changes by modifying culture conditions including serum-free media composition, oxygen tension (hyperoxic conditions), and growth factor concentrations to enable avian ESCs to maintain stem cell characteristics while scaling to large-volume bioreactor cultures. This resolves the contradiction by adjusting physical and chemical parameters to support both self-renewal and scalability.
Solution Approach 2:
The patent develops a universal culture system that can simultaneously support expansion of undifferentiated avian ESCs and their differentiation into multiple tissue types (muscle, fat, connective tissue) using the same base culture platform. This multi-functional approach enables both maintenance of stem cell properties and scalable production of differentiated tissues.
2Productivity
If traditional culture media with animal-derived serum are used, then cell growth support is improved, but consumer acceptance and cost-effectiveness deteriorate
Solution Approach 1:
The patent extracts and removes animal-derived serum components from the culture media, replacing them with defined serum-free formulations containing specific growth factors, amino acids, and nutrients. This extraction of problematic animal ingredients maintains cell growth support while improving consumer acceptance and reducing costs through standardized formulations.
Solution Approach 2:
The patent employs cost-effective, chemically defined media components that can be produced at scale without relying on expensive animal serum batches. The use of synthetic, reproducible ingredients reduces manufacturing variability and cost while eliminating consumer concerns about animal-derived materials.
3Productivity
If adherence to matrix is maintained for stem cell culture, then cell survival and proliferation are improved, but aggregate formation and suspension culture capability are reduced
Solution Approach 1:
The patent dynamically adjusts the culture system by transitioning cells from adherent to suspension conditions in a controlled manner. The serum-free media formulation and growth factor supplementation enable cells to adapt to changing physical conditions, forming stable aggregates in suspension while maintaining high survival and proliferation rates throughout the transition.
Data Source
AI summary
Primed cells, pluripotent stem cell aggregates and microtissues produced therefrom and uses of same for producing edible products.